Biodesix (BDSX) Q2 2026 Earnings Call Transcript
Biodesix (BDSX) reported Q2 2026 results and discussed clinical demand drivers for its Nodify lung nodule biomarkers. The company said March publication of a lung nodule validation study increased Nodify CDT orders for nodules as small as 4 mm. Q2 revenue rose 34% to $26.9M, diagnostic testing revenue $25.4M (+42%), gross margin 82%, and net loss was $7.3M. Full-year revenue outlook remains $108M to $114M.
How this was made
The 30-second read
Why it matters
Management attributes growth to clinical evidence (small nodule detection) and account penetration, while reporting strong gross margin and operating leverage. They also reiterate full-year revenue guidance of $108M to $114M and discuss sales force expansion and productivity.
Market read
Traders can update models around Biodesix’s growth rate, margin trajectory, and sales productivity assumptions using the reported Q2 metrics and maintained revenue guidance.
What to watch
The excerpt notes development services revenue timing and cash/ATM proceeds; without full balance-sheet and guidance assumptions, liquidity and burn trajectory risks may be underweighted.
Background
Biodesix is discussing commercial traction for its Nodify lung nodule testing franchise and reporting Q2 2026 financial results on an earnings call.
Ticker impact
Biodesix reported Q2 2026 revenue of $26.9M (+34% YoY) and gross margin of 82%, citing Nodify franchise demand and payer coverage.
Near-term bias positive if investors focus on the 34% revenue growth, 82% gross margin, and maintained $108M to $114M revenue outlook.
The article contains primary earnings metrics, margin improvement, and a specific guidance range, which typically drive repricing. However, the excerpt does not include consensus comparisons or management’s full Q&A, limiting conviction on incremental upside/downside.
Market effects
Supports the lung-diagnostics adoption narrative (Nodify CDT/XL2) and may reinforce investor appetite for profitable growth in molecular diagnostics.
No clear regional-specific impact mentioned.
Primarily US-focused clinical meeting references and US commercial execution; limited direct global read-through.
Counterpoint
Demand acceleration could be partly mix-driven (CDT vs XL2) and payer coverage improvements, which may not fully persist if reimbursement dynamics change.
Key entities
- companyBiodesix
Reported Q2 2026 revenue growth, gross margin improvement, and reiterated full-year revenue outlook on its earnings call.
- productNodify CDT
Management links increased orders to validation study results showing detection in nodules as small as 4 millimeters with low false positives.
- productNodify XL2
Management describes cross-utilization after providers start with smaller-nodule testing.
- conferenceATS (American Thoracic Society)
Referenced as venue for real-world clinical and economic data presentations supporting lung nodule program value.
